{"id":592586,"date":"2026-04-08T03:16:11","date_gmt":"2026-04-08T03:16:11","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/592586\/"},"modified":"2026-04-08T03:16:11","modified_gmt":"2026-04-08T03:16:11","slug":"2-classy-asx-healthcare-stocks-to-buy-before-the-next-market-surge","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/592586\/","title":{"rendered":"2 classy ASX healthcare stocks to buy before the next market surge"},"content":{"rendered":"\n

ASX healthcare stocks have taken a hit lately, but that could be setting up opportunity.<\/p>\n

Two of the ASX’s biggest names in the sector are under pressure, with CSL Ltd (ASX: CSL<\/a>) down 33% over the past six months and ResMed Inc (ASX: RMD<\/a>) sliding 20% over the same period at the time of writing.<\/p>\n

So, are these high-quality names primed for a comeback?<\/p>\n

\"A<\/p>\n

Image source: Getty Images<\/p>\n

CSL: Global leader in plasma therapies <\/p>\n

CSL has fallen out of favour, but the underlying business still looks incredibly strong.<\/p>\n

This is a global leader in plasma therapies and vaccines, supplying critical treatments for chronic and rare diseases. Demand for its products is highly resilient \u2014 patients need them regardless of economic conditions.<\/p>\n

That gives the $67 billion ASX healthcare stock<\/a> a defensive edge, backed by recurring revenue and strong global demand.<\/p>\n

Recent results <\/a>have been softer, with margin pressure, restructuring costs, and policy changes weighing on performance. That’s played a big role in the share price decline.<\/p>\n

But there are signs of recovery. Plasma collections are improving, margins are stabilising, and its vaccine business, Seqirus, continues to diversify earnings. This looks more like a reset than a structural decline.<\/p>\n

The main risks? Ongoing margin pressure, currency headwinds, and any delays in earnings recovery.<\/p>\n

Still, analysts remain firmly in the corner of the ASX healthcare stock.<\/p>\n

Broker sentiment is broadly positive, with most maintaining buy or outperform ratings. The average 12-month price target sits around $214.00 \u2014 implying 54% upside.<\/p>\n

ResMed: Market leader in sleep apnea <\/p>\n

ResMed has also been caught in the recent healthcare and tech sell-off, but its long-term story remains compelling.<\/p>\n

This ASX healthcare stock is a global leader in sleep apnea devices and digital health solutions. Its products improve patient outcomes and are increasingly integrated with cloud-based platforms \u2014 creating a sticky, recurring revenue<\/a> model.<\/p>\n

A major growth driver is rising awareness and diagnosis of sleep disorders, alongside expansion in digital health and remote monitoring.<\/p>\n

So why the sell-off? Concerns around competition, particularly from weight-loss drugs potentially reducing sleep apnea cases, have weighed on sentiment. Like CSL, it has also been hit by broader market rotation away from growth stocks.<\/p>\n

That said, the business continues to deliver solid performance and innovation.<\/p>\n

The risks include competitive pressures, regulatory changes, and any slowdown in patient growth.<\/p>\n

But analysts remain largely upbeat on the ASX healthcare stock.<\/p>\n

The average price target sits at $307.95, suggesting upside of around 37%. The most bullish forecasts go even further, tipping the stock could reach $371.80, implying gains of up to 66%.<\/p>\n

Foolish Takeaway <\/p>\n

CSL and ResMed have both been sold off, but their core businesses remain strong.<\/p>\n

If sentiment shifts and earnings momentum improves, these ASX healthcare stocks could be well positioned to lead the next market surge.<\/p>\n","protected":false},"excerpt":{"rendered":"ASX healthcare stocks have taken a hit lately, but that could be setting up opportunity. Two of the…\n","protected":false},"author":2,"featured_media":411489,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":{"0":"post-592586","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-au","9":"tag-australia","10":"tag-health","11":"tag-healthcare"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/592586","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=592586"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/592586\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/411489"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=592586"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=592586"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=592586"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}